Therapeutic Interventions in the Diabetic Heart

  • John H. McNeill
  • Brian Rodrigues
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 185)

Abstract

Chronic diabetics in general have a higher incidence of and mortality from cardiac disease [1,2]. A wide spectrum of cardiac problems plague the chronic diabetic and include left-ventricular dilatation and hypertrophy, lower stroke volume and cardiac output and abnormalities of left-ventricular ejection time and prolongation of the pre-ejection period [3–5]. Although studies have shown that the incidence of causative factors such as large and small vessel disease and autonomic neuropathy [6] are increased during diabetes, these factors cannot always be definitely implicated as contributing agents to myocardial problems, due to their absence in a significant number of diabetic patients [7]. These results suggest that a specific cardiomyopathy may be a causal factor in producing the increase in mortality and morbidity of diabetes [8,9].

Keywords

Cholesterol Lipase Selenium Methionine Cardiomyopathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kannel WB and McGee DL. Diabetes and cardiovascular disease: The Framingham Study. JAMA 241: 2035–2038, 1979.PubMedCrossRefGoogle Scholar
  2. 2.
    Palumbo PJ, Elveback CR and Conolly DC. Coronary artery disease and congestive heart failure in the diabetic: Epidemiological aspects. The Rochester Diabetes Project. In Clinical Cardiology and Diabetes, Scott RC, Ed., Futura, New York, p. 13, 1981.Google Scholar
  3. 3.
    Hamby RI, Zoneraich S and Sherman L. Diabetic cardiomyopathy. JAMA 229: 1749–1754, 1974.PubMedCrossRefGoogle Scholar
  4. 4.
    Regan TJ, Lyons MM and Ahmed SS. Evidence for cardiomyopathy in familial diabetes mellitus. J. Clin. Invest. 60: 885–889, 1977.CrossRefGoogle Scholar
  5. 5.
    D’Elia JA, Weinrauch LA, Healy RW, Libertino RW, Bradley RF and Leland OS. Myocardial dysfunction without coronary artery disease in diabetic renal failure. Am. J. Cardiol. 43: 193–199, 1979.PubMedCrossRefGoogle Scholar
  6. 6.
    Ledet B, Neubauer B, Christensen NJ, Lundback K. Diabetic cardiopathy. Diabetologia 16: 207–209, 1979.PubMedCrossRefGoogle Scholar
  7. 7.
    Ahmed SS, Jaferi GA, Narang RM and Regan TJ. Preclinical abnormality of left ventricular function in diabetes mellitus. Am. Heart J. 89: 153–158, 1975.PubMedCrossRefGoogle Scholar
  8. 8.
    Fein FS and Sonnenblick EH. Diabetic cardiomyopathy. Prog. Cardiovasc. Res. 27: 255–270, 1985.CrossRefGoogle Scholar
  9. 9.
    Galderisi M, Anderson KM, Wilson PWF and Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am. J Cardiol. 68:85–89, 1991.PubMedCrossRefGoogle Scholar
  10. 10.
    Regan TJ, Ettinger PO, Khan MI, Jesran MU, Lyons MM, Oldewurtel HA and Weber M. Altered myocardial function and metabolism in chronic diabetes mellitus without ischemia in dogs. Circ. Res. 35: 222–237, 1974.Google Scholar
  11. 11.
    Miller TB. Cardiac performance of isolated perfused hearts from alloxan diabetic rats. Am. J. Physiol. 236: 808–812, 1979.Google Scholar
  12. 12.
    Vadllamudi RVSV, Rodgers RL and McNeill JH. The effect of chronic alloxan- and streptozotocin-induced diabetes on isolated rat heart performance. Can. J. Physiol. Pharmacol. 60: 902–911, 1982.CrossRefGoogle Scholar
  13. 13.
    Fein FS, Kornstein LB, Strobeck JE, Capasso JM and Sonnenblick EH. Altered myocardial mechanics in diabetic rats. Circ. Res. 47: 922–933, 1980.PubMedGoogle Scholar
  14. 14.
    Rodrigues B and McNeill JH. Cardiac function in spontaneously hypertensive diabetic rats. Am. J. Physiol. 251: 571–580, 1986.Google Scholar
  15. 15.
    National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039–1057, 1979.Google Scholar
  16. 16.
    Marliss EB, Nakhooda AF, Poussier P and Sima AAF. The diabetic syndrome of the “BB” Wistar rat: Possible relevance to Type 1 (insulin-dependent) diabetes in man. Diabetologia 22: 225–232, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Rodrigues B and McNeill JH. Cardiac dysfunction in isolated perfused hearts from spontaneously diabetic BB rats. Can. J. Physiol. Pharmacol. 68: 514–518, 1990.PubMedCrossRefGoogle Scholar
  18. 18.
    Rodrigues B and McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovas. Res. 26:913–922, 1992.CrossRefGoogle Scholar
  19. 19.
    Jackson CV, McGarth GM, Tahiliani AG, Vadlamudi RVSV and McNeill JH. A functional and ultrastructural analysis of experimental diabetic rat myocardium: Manifestation of cardiomyopathy. Diabetes 34: 876–883, 1985.PubMedCrossRefGoogle Scholar
  20. 20.
    Rodrigues B, Cam MC and McNeill JH. Myocardial substrate metabolism: Implications for diabetic cardiomyopathy. J. Mol. Cell. Cardiol. 27: 169–179, 1995.PubMedCrossRefGoogle Scholar
  21. 21.
    Chattopadhyay J, Thompson EW and Schmid HHO. Elevated levels of non-esterified fatty acids in the myocardium of alloxan diabetic rats. Lipids 25: 307–310, 1990.PubMedCrossRefGoogle Scholar
  22. 22.
    Opie L.H. Effect of fatty acid on contractility and rhythm of the heart. Nature (Lond.) 227: 1055–1056, 1970.CrossRefGoogle Scholar
  23. 23.
    Garvey WG, Hardin G, Juhaszova M and Dominguez JH. Effects of diabetes on myocardial glucose transport system in rats: Implication for diabetic cardiomyopathy. Am. J. Physiol. 264: 837–844, 1993.Google Scholar
  24. 24.
    Randle PJ, Hales CN, Garland PB and Newsholme EA. The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785–789, 1963.PubMedGoogle Scholar
  25. 25.
    Kerby AK, Vary TC and Randle PJ. Molecular mechanisms regulating myocardial glucose oxidation. Basic. Res. Cardiol. 80 (Suppl 2): 93–96, 1985.Google Scholar
  26. 26.
    Wall SR and Lopaschuk GD. Glucose oxidation rates in fatty acid perfused isolated working hearts from diabetic rats. Biochim. Biophys. Acta 1006: 97–103, 1989.PubMedGoogle Scholar
  27. 27.
    Chen V, Ianuzzo CD, Fong BC and Spitzer JJ. The effects of acute and chronic diabetes on myocardial metabolism in rats. Diabetes 33:1078–1084, 1984.PubMedCrossRefGoogle Scholar
  28. 28.
    Vadlamudi RVSV, Rodgers RL and McNeill JH. The effect of chronic alloxan- and streptozotocin-induced diabetes on isolated rat heart performance. Can. J. Physiol. Pharmacol. 60: 902–911, 1982.PubMedCrossRefGoogle Scholar
  29. 29.
    McGarth GM and McNeill JH. Cardiac ultrastructural changes in streptozotocin-induced diabetic rats: Effects of insulin treatment. Can. J. Cardiol. 2:164–169, 1986.Google Scholar
  30. 30.
    Heyliger CE, Rodrigues B and McNeill JH. Alterations of cardiac muscle membranes in hypertension and diabetes mellitus. In Membrane Abnormalities in Hypertension and Diabetes Mellitus. Kwan CY (Ed), CRC Press Inc., Florida, pp.91–116, 1989.Google Scholar
  31. 31.
    Lopaschuk GD, Eibschutz B, Katz S and McNeill JH. Depression of calcium transport in sarcoplasmic reticulum from diabetic rats: Lack of involvement by specific regulatory mediators. Gen. Pharmac. 15: 1–5, 1984.CrossRefGoogle Scholar
  32. 32.
    Lopaschuk GD, Katz S and McNeill JH. The effect of alloxan-and streptozotocin-induced diabetes on calcium transport in rat cardiac sarcoplasmic reticulum. The possible involvement of long chain acylcarnitines. Can. J. Physiol. Pharmacol. 61: 439–448, 1983.PubMedCrossRefGoogle Scholar
  33. 33.
    Yu Z, Tibbits GF and McNeill JH. Cellular function of diabetic cardiomyocytes: Contractility, rapid cooling contracture, and ryanodine binding. Am. J. Physiol. 266: 2082–2089, 1994.Google Scholar
  34. 34.
    McNeill JH and Tahiliani AG. Diabetes-induced cardiac changes. Trends Pharmacol. Sci. 7: 364–367, 1986.CrossRefGoogle Scholar
  35. 35.
    Tolman EL, Barris E, Burns M, Prasini A and Partridge R. Effects of vanadium on glucose metabolism in vitro. Life Sci. 25: 1159–1164, 1979.PubMedCrossRefGoogle Scholar
  36. 36.
    Tamura S, Brown TA, Dubler RE and Larner. Insulin-like effect of vanadate on adipocyte glycogen synthase and on phosphorylation of 95,000 dalton subunit of insulin receptor. Biochem. Biophys. Res. Commun. 113: 80–86, 1983.PubMedCrossRefGoogle Scholar
  37. 37.
    Heyliger CE, Tahiliani AG and McNeill JH. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science 227: 1474–1477, 1985.PubMedCrossRefGoogle Scholar
  38. 38.
    Takada K, Temma K and Akera T. Inotropic effects of vanadate in isolated rat and guinea-pig heart under conditions which modify calcium pools involved in contractile activation. J. Pharmacol. Exp. Ther. 222: 132–139, 1982.Google Scholar
  39. 39.
    Ramanadham S, Mongold JJ, Brownsey RW, Cros GH and McNeill JH. Oral vanadyl sulfate in treatment of diabetes mellitus in rats. Am. J. Physiol. 257: 904–911, 1989.Google Scholar
  40. 40.
    Ramanadham S, Brownsey RW, Cros GH, Mongold JJ and McNeill JH. Sustained prevention of myocardial and metabolic abnormalities in diabetic rats following withdrawal from oral vanadyl treatment. Metabolism 38: 1022–1028, 1989.PubMedCrossRefGoogle Scholar
  41. 41.
    Pederson RA, Ramanadham S, Buchan AMJ and McNeill JH. Long-term effects of vanadyl treatment on streptozocin-induced diabetes in rats. Diabetes 38: 1390–1393, 1989.PubMedCrossRefGoogle Scholar
  42. 42.
    Battell ML, Yuen VG and McNeill JH. Treatment of BB rats with vanadyl sulphate. Pharmacol. Commun. 1: 291–301, 1992.Google Scholar
  43. 43.
    Underwood EJ. Vanadium. In Trace elements in human and animal nutrition. Academic Press, New York, pp 388–397, 1977.Google Scholar
  44. 44.
    Cam MC, Cros GH, Serrano JJ, Lazaro R and McNeill JH. In vivo antidiabetic actions of naglivan, an organic compound in streptozotocin-induced diabetes. Diab. Res. Clin. Prac. 20: 11–121, 1993.CrossRefGoogle Scholar
  45. 45.
    McNeill JH, Yuen VG, Hoveyda HR and Orvig C. Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. J. Med. Chem. 35: 1489–1491, 1992.PubMedCrossRefGoogle Scholar
  46. 46.
    Ramanadham S, Cros GH, Mongold JJ, Serrano JJ, McNeill JH. Enhanced in vivo sensitivity of vanadyl-treated diabetic rats to insulin. Can. J. Physiol. Pharmacol. 68: 486–491, 1990.PubMedCrossRefGoogle Scholar
  47. 47.
    Yuen VG, Orvig C, Thompson KH and McNeill JH. Improvement in cardiac dysfunction in strepotozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV). Can. J. Physiol. Pharmacol. 71: 270–276, 1992.CrossRefGoogle Scholar
  48. 48.
    Yuen VG, Orvig C and McNeill JH. Comparison of the glucose lowering properties vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Can. J. Physiol. Pharmacol., (submitted).Google Scholar
  49. 49.
    Ezaki O. The insulin-like effects of selenate in rat adipocytes. J. Biol. Chem. 265:1124–1128, 1990.PubMedGoogle Scholar
  50. 50.
    McNeill JH, Delgatty HLM and Battell ML. Insulin like effects of sodium selenate in streptozotocin-induced diabetic rats. Diabetes 40: 1675–1678, 1991.PubMedCrossRefGoogle Scholar
  51. 51.
    Rodrigues B, Xiang H and McNeill JH. Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 37: 1358–1364, 1988.PubMedCrossRefGoogle Scholar
  52. 52.
    Heyliger CE, Rodrigues B and McNeill JH. Effect of choline and methionine treatment on cardiac dysfunction of diabetic rats. Diabetes 35: 1152–1157, 1986.PubMedCrossRefGoogle Scholar
  53. 53.
    Rodrigues B, Goyal RK and McNeill JH. Effects of hydralazine on streptozotocin-induced diabetic rats: prevention of hyperlipidemia and improvement in cardiac function. J. Pharmacol. Exp. Ther. 237: 292–299, 1986.PubMedGoogle Scholar
  54. 54.
    Rodrigues B, Grassby PF, Battell ML, Lee SYN and McNeill JH. Hypertriglyceridemia in experimental diabetes: relationship to cardiac dysfunction. Can. J. Physiol. Pharmacol. 72: 447–455, 1994.PubMedCrossRefGoogle Scholar
  55. 55.
    Tulloch BR, Lewis B and Fraser TR. Triglyceride metabolism in thyroid disease. Lancet 1: 391–394, 1973.PubMedCrossRefGoogle Scholar
  56. 56.
    DeMartino GN and Goldberg AL. A possible explanation for myxedema and hypercholesterolemia in hypothyroidism. Enzyme 26:1–7, 1981.PubMedGoogle Scholar
  57. 57.
    Tahiliani AG and McNeill JH. Lack of effect of thyroid hormone on diabetic rat heart function and biochemistry. Can. J. Physiol. Pharmacol. 62: 617–621, 1984.PubMedCrossRefGoogle Scholar
  58. 58.
    Dillman WH. Influence of thyroid hormone on myosin ATPase activity and myosin isoenzyme distribution in the heart of diabetic rats. Metabolism 31:199–204, 1982.CrossRefGoogle Scholar
  59. 59.
    Xiang H, Heyliger CE and McNeill JH. Effect of myo-Inositol and T3 on myocardial lipids and cardiac function in streptozotocin-induced diabetic rats. Diabetes 37: 1542–1548, 1988.PubMedCrossRefGoogle Scholar
  60. 60.
    Tahiliani AG and McNeill JH. Prevention of diabetes-induced myocardial dysfunction in rats by methyl palmoxirate and triiodothyronine treatment. Can. J. Physiol. Pharmacol. 63: 925–931, 1985.PubMedCrossRefGoogle Scholar
  61. 61.
    Afzal N. Ganguly PK, Dhalla KS, Pierce GN, Singal PK and Dhalla NS. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37: 936–942, 1988.PubMedCrossRefGoogle Scholar
  62. 62.
    Afzal N. Pierce GN, Elimban V, Beamish RE and Dhalla NS. Influence of verapamil on some subcellular defects in diabetic cardiomyopathy. Am. J. Physiol. 256: 453–458, 1989.Google Scholar
  63. 63.
    Nicholl TA, Lopaschuk GD and McNeill JH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart. Am. J. Physiol. 261: 1053–1059, 1991.Google Scholar
  64. 64.
    Verma S and McNeill JH. Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am. J. Physiol. 266: 714–719, 1994.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • John H. McNeill
  • Brian Rodrigues

There are no affiliations available

Personalised recommendations